SRPK1 and non-small cell lung carcinoma: Moreover, the non-kinase structural domain of SRPK1 can facilitate its interaction with GSK3β, promoting GSK3β autophosphorylation at the Ser9 site, thus enhancing gefitinib resistance in NSCLC.27